HopeStage
Back to all studies
RecruitingNCT06706232

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolarity II Depression and Suicide prevention

Official study title

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

Medication studyAges 25–70United States
The study in practice

Understand this study

Who could participate?

This study is for people with type II bipolarity. Listed age limits: 25 years to 70 years. Other eligibility criteria apply.

Listed locations
Houston, United StatesSee all locations and recruitment
Activities
Medication described in the protocol · Behavioural activities described in the protocol
Compensation
Payment and expense reimbursement have not been verified.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: July 7, 2025
Recruitment status
Recruiting
Enrollment listed in the registry
10
Sponsor
The University of Texas Health Science Center, Houston
Sponsor type
University
Study type
Drug
Intervention type
Psychotherapy / behavioral intervention, Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 25 Years to 70 Years
Official registry ID
NCT06706232

Want help reviewing this study?

Loading the security check...
Study ID: NCT06706232. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Recruiting

Houston

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is The University of Texas Health Science Center, Houston, a university.

Does this study involve medication?

Yes. The study involves medication, including Psilocybin.

Who can participate?

This study is for people with type II bipolarity. Listed age limits: 25 years to 70 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me